Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|7|2|150-157

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.7, Iss.2, 2012-05, pp. : 150-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholesterol-lowering drugs and Alzheimer’’s disease

By Eckert Gunter P   Müüller Walter E   Wood W Gibson  

Future Lipidology, Vol. 2, Iss. 4, 2007-08 ,pp. : 423-432

Future Medicine

Access to resources Recommend Favorite

The Ebbs and Flows in the Development of Cholesterol‐Lowering Drugs: Prospects for the Future

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 1, 2014-07 ,pp. : 64-73

John Wiley & Sons Inc

Access to resources Recommend Favorite

Barriers to EBM

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 20, Iss. 6, 2014-12 ,pp. : 793-802

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multifactorial Lifestyle Interventions in the Primary and Secondary Prevention of Cardiovascular Disease and Type 2 Diabetes Mellitus—A Systematic Review of Randomized Controlled Trials

By Angermayr Lucia  

Annals of Behavioral Medicine, Vol. 40, Iss. 1, 2010-08 ,pp. : 49-64

Springer Publishing Company

Access to resources Recommend Favorite

Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose‐lowering interventions

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 238-244

John Wiley & Sons Inc

Access to resources Recommend Favorite